本文選題：結(jié)核　切入點：肺　出處：《重慶醫(yī)學(xué)》2016年34期 　論文類型：期刊論文

【摘要】：目的運用分子線性探針技術(shù)(MTBDRplus)對2個月末涂片陽性的初治肺結(jié)核患者進(jìn)行快速耐藥檢測及個體化治療指導(dǎo),并觀察其預(yù)后。方法選擇基線及2個月末痰涂片仍為陽性的初治肺結(jié)核患者隨機分兩組,分別予以傳統(tǒng)直接觀察(或面視)下的短程化療(Directly Observed Treatment+short course chemotherapy,DOTs)方案及分子藥敏指導(dǎo)治療,并比較預(yù)后。結(jié)果在分子藥敏指導(dǎo)治療組中成功率,完全敏感的為74.4%,單耐異煙肼為87.5%,單耐利福平100.0%,耐多藥結(jié)核75.0%;DOTs方案組中,成功率為單耐異煙肼25.0%,單耐利福平耐和耐多藥結(jié)核均為0.0%。兩組預(yù)后χ~2分析顯示差異有統(tǒng)計學(xué)意義(P=0.044)。結(jié)論 MTBDRplus應(yīng)用在2個月末涂陽初治肺結(jié)核患者中可改善預(yù)后。
[Abstract]:Objective to apply molecular linear probe technique to detect drug resistance in two months smear-positive patients with primary pulmonary tuberculosis and to guide individual treatment. Methods the patients with primary pulmonary tuberculosis who were still positive for sputum smear at baseline and at the end of 2 months were randomly divided into two groups. The patients were treated with direct Observed Treatment short course chemotherapy under traditional direct observation (or face view) and molecular chemosensitivity, and the prognosis was compared. Results the success rate in the treatment group guided by molecular drug sensitivity was higher than that in the control group. Total sensitivity was 74.4, isoniazid was 87.5, rifampicin was 100.0, MDR-TB was 75.0 in DOTs group, The success rate was 25. 0% for isoniazid, 0. 0 for rifampicin resistance and 0. 0 for multidrug resistant tuberculosis. 蠂 2 analysis showed that there was a significant difference in prognosis between the two groups. Conclusion MTBDRplus can improve the prognosis of pulmonary tuberculosis at the end of 2 months.
【作者單位】： 西南醫(yī)科大學(xué)附屬醫(yī)院感染科;浙江諸暨市人民醫(yī)院感染科;杭州市疾病預(yù)防控制中心;復(fù)旦大學(xué)附屬華山醫(yī)院感染科;
【基金】：四川省瀘州市科技局資助項目[2014-s-45(7/12)] 西南醫(yī)科大學(xué)附屬第一醫(yī)院博士基金(14047)
【分類號】：R521

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 李輝;馬曉光;石潔;王瑜;閆國蕊;楊洪毅;李強;趙雁林;;線性探針法MTBDRplus用于涂陽肺結(jié)核的耐多藥檢測研究[J];中國衛(wèi)生檢驗雜志;2013年02期

，

本文編號：1623115